Register for our free email digests:
Division of Valneva SE
Latest From Intercell AG
This week’s roundup includes high-level appointments by Almirall, Hookipa Biotech and RXi Pharmaceuticals, in addition to CEO appointments by Karolinska Development and ReForm Biologics and various board announcements by companies including Faron and Redx.
Werner Lanthaler talks to Jo Shorthouse about partnering with big pharma on drug discovery, remaining authentic, and creating the 'half pregnant' company that Evotec is today.
Michael Buschle, Glenmark's chief scientific officer and president (biologics), clearly values the Indian firm's "entrepreneurial culture" and "flexibility", even if it means doing cutting edge R&D with relatively smaller budgets than Big Pharma enjoys.
We all know about the risks of new drug development and the cost barriers to patient access to those products when they are approved. These problems are particularly acute where antibacterials are concerned, as resistance grows to even some of the most commonly used drugs, all the more so in developing countries where infectious disease takes a disproportionate toll.
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Infectious & Viral Diseases
- Intercell Biomedical Research & Development AG
- Western Europe
- Parent & Subsidiaries
- Valneva SE
- Senior Management
Thomas Lingelbach, CEO
Reinhard Kandera, CFO
Alexander von Gabain, CSO
Staph Leavenworth Bakali, CBO
- Contact Info
Phone: (43) 1-20620
Campus Vienna Biocenter 3
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.